Literature DB >> 6135298

The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.

D A Johnson, G Pasterski, J M Ludlow, K Street, R D Taylor.   

Abstract

In a prospective follow-up the outcome of 60 chronic schizophrenic patients who discontinued neuroleptic therapy after remaining stable 12-48 months was compared with controls continuing medication. Not only did the drug-discontinued patients have more relapses (P less than 0.001), but the form of relapse was both more severe and acute, resulting in differences of self-injury (P less than 0.05), anti-social behaviour (P less than 0.01), inpatient admissions (P less than 0.001), and the use of compulsory powers (P less than 0.01). In patients who relapsed, both social and work function was affected adversely for some months. Patients who remained relapse-free without drugs (20%) had a level of work and social function similar to medicated patients. At the end of 18 months the patients who discontinued depot maintenance therapy were found to have been prescribed one-third more neuroleptic drugs than controls, with a possible increase in the risk of long-term tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135298     DOI: 10.1111/j.1600-0447.1983.tb00351.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  23 in total

1.  A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966-1993.

Authors:  Adil E Shamoo; Dianne N Irving; Patricia Langenberg
Journal:  Sci Eng Ethics       Date:  1997-10       Impact factor: 3.525

2.  Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

Authors:  Diana De Graeve; Ann Smet; Angelika Mehnert; Sue Caleo; Houda Miadi-Fargier; Guillermo Jasso Mosqueda; Damien Lecompte; Joseph Peuskens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors:  Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  The effects of early and sustained intervention on the long-term morbidity of schizophrenia.

Authors:  R J Wyatt; I D Henter
Journal:  J Psychiatr Res       Date:  1998 May-Aug       Impact factor: 4.791

Review 5.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 6.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 7.  Medication-free research in early episode schizophrenia: evidence of long-term harm?

Authors:  John R Bola
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

Review 8.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

9.  Do antipsychotics limit disability in schizophrenia? A naturalistic comparative study in the community.

Authors:  Jagadisha Thirthalli; Basappa K Venkatesh; Magadi N Naveen; Ganesan Venkatasubramanian; Udupi Arunachala; Kengeri V Kishore Kumar; Bangalore N Gangadhar
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

10.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.